Results 61 to 70 of about 10,318 (317)

Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study

Cardiovascular Diabetology
Background Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients ...
Jasmine Melissa Madsen, Alexander Krüger Kjaer, Jacob Thomsen Lønborg, Lars Køber, Charlotte Glinge, Reza Jabbari, Thomas Engstrøm   +6 more
doaj   +1 more source

Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release

Journal of Hand Surgery Global Online
Purpose: Glucagon-like peptide-1 receptor agonist (GLP-1RA) use continues to rise because of its efficacy in glycemic control and weight reduction. There are sparse data on the implications of GLP-1RA therapy on surgical outcomes.
Nicholas C. Bank, MD, Stephen J. Perle, BS, Bradley J. Lauck, BA, Alecia J. Rajesh, BS, Alexander D. Jeffs, MD, Reid W. Draeger, MD   +5 more
doaj   +1 more source

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial [PDF]

, 2016
Background: Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk.
A Collier, A Goyal, A Ludman, A. Comlekci, AE Sumner, American Diabetes Association, American Diabetes Association, BA Swinburn, BM Scirica, C Daousi, CJ Lavie, CJ Li, D Wormser, E Selvin, E. Franek, EA Molenaar, Expert Panel on Detection, F. M. M. Baeres, I Chopra, I. Raz, ID Caterson, IM Rückert, J Logue, J. Petrie, J. Vidal, JB Albu, K Niswender, KG Alberti, L Blonde, L Guenette, L. A. Leiter, L. Masmiquel, L. van Gaal, LA Vázquez, LG Goh, LN McEwen, M Bastien, M Leenders, M Ng, M. Eriksson, MA Bethel, MD Jensen, ME Farkouh, MJ Davies, NJ Stone, NR Jones, P Li, P Weeke, RR Wing, S Baxi, S. Bain, S. Jacob, S. P. Marso, SK Paul, SP Marso, T Tillin, The Emerging Risk Factors Collaboration, UE Ntuk, V Bhan, X Pi-Sunyer   +59 more
core   +2 more sources

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies [PDF]

, 2021
Introduction: The aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT).
Candido, Riccardo, Consoli, Agostino, Di Bartolo, Paolo, Disoteo, Olga, Fadini, Gian Paolo, Laviola, Luigi   +5 more
core   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by the 13C breath test or paracetamol absorption technique.
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara, Masato Kasuga   +10 more
doaj   +1 more source

Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis

BMJ Open
Objective This study aimed to evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RA) in reducing body mass index (BMI) and blood glucose levels in individuals with type 2 diabetes mellitus (T2DM) using the difference-in ...
Ammarin Thakkinstian, John Attia, Thunyarat Anothaisintawee, Gareth J Mckay, Sukanya Siriyotha, Panu Looareesuwan, Hataikarn Nimitphong   +6 more
doaj   +1 more source

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain [PDF]

, 2016
Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment.
Aguilera, Eva, Ampudia Blasco, Francisco Javier, Anglada, Jordi, Arguelles, Iñaqui, Bellido Guerrero, Diego, Brito Sanfiel, Miguel Ángel, Casanueva, Felipe, Conget, Ignacio, Cuatrecasas, Guillem, De Castro Hernández, Paloma, De la Cuesta, Carmen, De Teresa Parreño, Luis, Detournay, Bruno, Escalada, Francisco Javier, Fernández Catalina, Pablo, Garcia Puig, Juan, García, Honorato, Gaztambide, Sonia, Giménez, Margarita, Gómez Peralta, Fernando, Gómez, Luis Alberto, Hernández Herrero, Cristina, Hernández Mijares, Antonio, Mangas Cruz, Miguel Ángel, Manzanares, Jose María, Martínez, Encarna, Masmiquel, Lluís, Mauricio, Dídac, Merino Torres, Juan Francisco, Miralles García, José Manuel, Muros, Teresa, Ortega, Rafael, Pérez Maraver, Manuel, Soto González, Alfonso, Tréscoli, Carlos, Vinagre, Irene   +35 more
core   +4 more sources

Long-acting GLP-1RAs

JAAPA, 2020
ABSTRACT Over recent decades, an improved understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) and glucose regulation has led to innovative research and new treatment paradigms. The discovery of the gut peptide glucagon-like peptide-1 (GLP-1) and its role in glucose regulation paved the way for the class of GLP-1 receptor ...
Ji Hyun, Chun, Amy, Butts
openaire   +4 more sources

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source